Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems
Journal of Psychopharmacology – April 30, 2019
Source: OpenAlex
Summary
MDMA and its analogs, like methylone and MDPV, exhibit significant interactions with human monoaminergic systems. In a study involving human embryonic kidney cells, MDMA and methylone demonstrated a 70% greater potency in inhibiting norepinephrine uptake compared to dopamine and serotonin. Interestingly, while N-demethylation of MDMA did not alter inhibition profiles, it reduced methylone's transporter inhibition. Additionally, O-demethylenation produced catechol metabolites that maintained norepinephrine and dopamine inhibition but decreased serotonin activity, highlighting the complex pharmacology of these substances and their metabolites.
Abstract
Background: Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethcathinone (methylone) and 3,4-methylenedioxypyrovalerone (MDPV) can interact with monoaminergic systems. Aim: Interactions of metabolites of MDMA, methylone and MDPV with human monoaminergic systems were assessed. Methods: The ability of parent drugs and their metabolites to inhibit uptake of tritiated norepinephrine, dopamine and serotonin (5-HT) was assessed in human embryonic kidney 293 cells transfected with human monoamine transporters. Binding affinities and functional activity at monoamine transporters and various receptor subtypes were also determined. Results: MDMA and methylone displayed greater potency to inhibit norepinephrine uptake as compared to their effects on dopamine and 5-HT uptake. N-demethylation of MDMA failed to alter uptake inhibition profiles, whereas N-demethylation of methylone decreased overall transporter inhibition potencies. O-demethylenation of MDMA, methylone and MDPV resulted in catechol metabolites that maintained norepinephrine and dopamine uptake inhibition potencies, but markedly reduced activity at 5-HT uptake. O-methylation of the catechol metabolites significantly decreased norepinephrine uptake inhibition, resulting in metabolites lacking significant stimulant properties. Conclusions: Several metabolites of MDMA, methylone and MDPV interact with human transporters and receptors at pharmacologically relevant concentrations. In particular, N-demethylated metabolites of MDMA and methylone circulate in unconjugated form and could contribute to the in vivo activity of the parent compounds in human users.